Evidence map›Paper›PMID 33394377›Full record

ArticleHead and neck pathology2021

SS18 Break-Apart Fluorescence In Situ Hybridization is a Practical and Effective Method for Diagnosing Microsecretory Adenocarcinoma of Salivary Glands.

Justin A Bishop, Prasad Koduru, Brandon M Veremis, Bahram R Oliai, Ilan Weinreb, Lisa M Rooper, Brendan C Dickson, Elizabeth G Demicco

Open access · greenAbstract read
In one paragraph

Article in Head and neck pathology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 35 citations in OpenAlex.

  1. Review
  2. Article
  3. Salivary gland microsecretory adenocarcinoma: a case series study and literature review.Virchows Archiv : an international journal of pathology · 2026
    Review
  4. Article
  5. Review
  6. Review
  7. Microsecretory adenocarcinoma of the external ear canal.Journal of cutaneous pathology · 2023
    Article
  8. Article
  9. Diagnostic Value of MAML2 Rearrangements in Mucoepidermoid Carcinoma.International journal of molecular sciences · 2022
    Article
  10. Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 2 countries.

Justin A BishopDepartment of Pathology, University of Texas Southwestern Medical Center, Clements University Hospital UH04.250, 6201 Harry Hines Blvd., Dallas, TX, 75390, USA. Justin.Bishop@UTSouthwestern.edu.ORCID http://orcid.org/0000-0002-9743-4360
Prasad KoduruDepartment of Pathology, University of Texas Southwestern Medical Center, Clements University Hospital UH04.250, 6201 Harry Hines Blvd., Dallas, TX, 75390, USA.
Brandon M VeremisDepartment of Pathology, Mount Sinai Hospital, New York, NY, USA.
Bahram R OliaiProPath, Dallas, TX, USA.
Ilan WeinrebDepartment of Pathology, University Health Network, Toronto, ON, Canada.
Lisa M RooperDepartment of Pathology, The Johns Hopkins Hospital, Baltimore, MD, USA.
Brendan C DicksonDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
Elizabeth G DemiccoDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
Mount Sinai Hospital · CAJohns Hopkins Hospital · USMount Sinai Hospital · USPropath Services (United States) · USThe University of Texas Southwestern Medical Center · USUniversity Health Network · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Molecular analysis has allowed for refinement of salivary gland tumor classification and, in some cases, the recognition of entirely new tumor types. Microsecretory adenocarcinoma (MSA) is a salivary gland tumor described in 2019 characterized by microcystic growth, bland cytomorphology, luminal secretions, fibromyxoid stroma, and S100/p63 positivity with negative p40. Most important, MSA is defined by MEF2C-SS18 fusion. While this fusion has, to this point, been detected by next-generation sequencing, this is a technique that is currently inaccessible in most diagnostic laboratories. On the other hand, SS18 break-apart fluorescence in situ hybridization (FISH) is widely available and frequently used as an adjunct for diagnosing synovial sarcoma. It is not known if SS18 break-apart FISH is positive in tumors with MEF2C-SS18, or if it is entirely specific for MSA. Break apart FISH for SS18 was performed on 4 cases of MSA, as well as 8 tissue microarrays (TMAs) containing 423 various salivary gland carcinomas: 26 acinic cell carcinomas, 35 adenocarcinomas not otherwise specified, 96 adenoid cystic carcinomas, 3 basal cell adenocarcinomas, 20 epithelial-myoepithelial carcinomas, 15 hyalinizing clear cell carcinomas, 3 intraductal carcinomas, 12 myoepithelial carcinomas, 117 mucoepidermoid carcinomas, 30 polymorphous adenocarcinomas, 45 salivary duct carcinomas, 19 secretory carcinomas, and 2 undifferentiated carcinomas. SS18 break-apart FISH was also performed on whole slides of 2 tumors from the TMAs. All MSA cases demonstrated classic split patterns on SS18 break-apart FISH. On the TMAs, 374 cases were evaluable by FISH, and 372 cases were clearly negative for SS18 rearrangement. Two cases, both mucoepidermoid carcinomas, had rare split signals below the positivity threshold of 12% on their TMA cores, so FISH was performed on whole sections. On the whole sections both tumors were unequivocally negative for SS18 rearrangement. Taken together, SS18 break-apart FISH was 100% sensitive and 100% specific for a diagnosis of MSA. SS18 break-apart FISH, a diagnostic tool widely available in pathology laboratories, appears to be a highly accurate method for diagnosing MSA of salivary glands. Accordingly, this new tumor type may be molecularly confirmed without needing to resort to highly specialized techniques like next-generation sequencing.

Indexed as

AdenocarcinomaHumansIn Situ Hybridization, FluorescenceProto-Oncogene ProteinsRepressor ProteinsSalivary Gland NeoplasmsProto-Oncogene ProteinsRepressor ProteinsSS18 protein, humanFluorescence in situ hybridizationMEF2C-SS18Microsecretory adenocarcinomaSalivary gland neoplasms

Identifiers

PMID33394377
PMCPMC8385014
OpenAlexW3119567787

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.